Status:
COMPLETED
Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma
Lead Sponsor:
Fred Hutchinson Cancer Center
Conditions:
Multiple Myeloma
Plasma Cell Neoplasm
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Chemoprotective agents may protect normal cells from the side effects of chemotherapy. Ice chips or saline mouth rinse may lessen the severity or help prevent symptoms of mucositis or mouth...
Detailed Description
OBJECTIVES: * Compare the efficacy of administering ice chips vs room temperature normal saline oral rinse before, during, and after melphalan administration, in terms of reducing or eliminating grad...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of multiple myeloma
- Scheduled to undergo an autologous peripheral blood stem cell transplantation (PBSCT) for multiple myeloma on protocol FHCRC-1137.00
- Scheduled to receive a regimen of single-agent melphalan at a dose of 200 mg/m\^2 before PBSCT
- PATIENT CHARACTERISTICS:
- Age
- Over 18
- Performance status
- Not specified
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- See Disease Characteristics
- Chemotherapy
- See Disease Characteristics
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- Not specified
- Other
- No concurrent artificial saliva on the day of melphalan infusion (day -2)
Exclusion
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00118339
Start Date
July 1 2003
End Date
May 1 2006
Last Update
September 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-1024